Engineering a BMP2-risedronate complex with sustained release for osteoporosis therapy.

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Drug Delivery Systems

Background:

• Human bone morphogenetic protein 2 (BMP2) is crucial for bone formation but faces challenges with conventional delivery systems causing rapid release and side effects.
• Developing controlled delivery methods for BMP2 is essential to improve its therapeutic efficacy in osteogenesis.

Purpose of the Study:

• To create an ionic complex of BMP2 with risedronate for improved osteogenic delivery.
• To evaluate the physicochemical properties, in vitro bioactivity, and in vivo performance of the BMP2-risedronate complex in hydrogels.

Main Methods:

• Fabrication of a BMP2-risedronate ionic complex using an ion-pairing method.
• Characterization of the complex using Fourier-transform infrared spectroscopy, ultra-resolution imaging, particle size analysis, polydispersity index, and zeta potential measurements.
• In vitro studies with C2C12 cells and in vivo studies using hydrogel formulations for controlled release and osteogenic efficacy assessment.

Main Results:

• The BMP2-risedronate complex showed high complexation efficiency (>95%) and stable physicochemical properties.
• In vitro studies confirmed that the complex effectively induced osteoblastic differentiation in C2C12 cells.
• Hydrogel incorporation led to controlled BMP2 release, and in vivo studies demonstrated enhanced osteogenic efficacy.

Conclusions:

• The BMP2-risedronate ionic complex offers a stable and effective system for BMP2 delivery.
• This novel complex, when incorporated into hydrogels, provides sustained release and improved osteogenic outcomes.
• The BMP2-risedronate complex represents a promising advancement for localized BMP2 delivery in osteogenesis therapy.